GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2007

Menarini Set to Initiate Phase III Trials on Its Ovarian Cancer Vaccine

  • Goodwin Biotechnology (GBI) has completed the manufacture of the mAb Abagovomab,  which is the active principle of Menarini Group’s Phase III ovarian cancer vaccine.

    The mAb, produced to standards fully compliant with U.S. and European requirements, will be used to kick off the initial phase of a multicenter clinical trial known as MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab). Abagovomab will be administered as a maintenance therapy after surgery and first-line platinum plus taxane chemotherapy with the aim to prevent the reappearance of tumor and prolong survival. Around 900 women will be enrolled, according to Menarini.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?